Join Growin Stock Community!

Mind medicine (mindmed) inc.MNMD.US Overview

US StockHealthcare
(No presentation for MNMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MNMD AI Insights

MNMD Overall Performance

MNMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MNMD Recent Performance

-1.38%

Mind medicine (mindmed) inc.

0.05%

Avg of Sector

-0.31%

S&P500

MNMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MNMD Key Information

MNMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MNMD Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Price of MNMD

MNMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MNMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
11.88
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
11.88
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MNMD's latest earnings report released?

    The most recent financial report for Mind medicine (mindmed) inc. (MNMD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MNMD's short-term business performance and financial health. For the latest updates on MNMD's earnings releases, visit this page regularly.

  • How much cash does MNMD have?

    At the end of the period, Mind medicine (mindmed) inc. (MNMD) held Total Cash and Cash Equivalents of 257.84M, accounting for 0.59 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MNMD's EPS continuing to grow?

    According to the past four quarterly reports, Mind medicine (mindmed) inc. (MNMD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.51. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MNMD?

    Mind medicine (mindmed) inc. (MNMD)'s Free Cash Flow (FCF) for the period is -72.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 186.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MNMD?

    The latest valuation data shows Mind medicine (mindmed) inc. (MNMD) has a Price-To-Earnings (PE) ratio of -5.93 and a Price/Earnings-To-Growth (PEG) ratio of 0.17. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.